Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with multiple myeloma that has recurred despite treatment (relapsed) or did not respond to treatment (refractory). The study is evaluating an experimental drug called oprozomib. Oprozomib is taken orally and will be given at different dose levels in combination with pomalidomide and dexamethasone.

Oprozomib works by preventing the breakdown of certain proteins in cell, causing the cells to die. Cancer cells are more susceptible to these effects than normal cells. Pomalidomide is designed to change the immune system, which may interfere with the development of blood vessels that help support tumor growth. Dexamethasone is a steroid that reduces inflammation. Pomalidomide and dexamethasone are FDA-approved.

The study has two parts—Phase 1b followed by Phase 3. We are currently enrolling for the Phase 1b study.

In Phase 1b, participants will receive different dose levels of oprozomib and pomalidomide to determine the best dose levels to use in combination with dexamethasone. All participants will receive oprozomib, pomalidomide and dexamethasone.

Treatment cycles are 28 days. Participants will receive:

  • Oprozomib (or placebo in Phase 3, Group 2) once daily on Days 1-5 and 15-19 of each cycle
  • Pomalidomide on Days 1-21 of each cycle
  • Dexamethasone on Days 1-2, 8-9, 15-16 and 22-23 of each cycle

Participants will continue on study treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key eligibility:

  • Men and women age 18 and older
  • Multiple Myeloma
  • Relapsed/refractory after at least 2 lines of standard therapy including:
      - 2 consecutive cycles of both bortezomib (Velcade) and lenalidomide or thalidomide
  • Detailed eligibility reviewed when you contact the study team

Contact:
Linda Tegnestam, R.N.
Email: lit2011@med.cornell.edu
Phone: (212) 746-1480

Kathleen Pogonowski, R.N.
Email: kap9111@med.cornell.edu 
Phone: (212) 746-6738

Disease Status and/or Stage

Primary Refractory or Relapsed and Refractory Multiple Myeloma

Sponsor

Onxy

Principal Investigator

Ruben Niesvizky, M.D.

Protocol ID

WCMC IRB # 1310014409


Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please e-mail:
Erica Bersin
Manager, Subject Recruitment & Communications
(646) 962-8232
erb3001@med.cornell.edu
jcto.weill.cornell.edu

Top of page